Literature DB >> 25082342

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.

Kami Maddocks1, Amy S Ruppert2, Rebekah Browning3, Jeffrey Jones4, Joseph Flynn4, Cheryl Kefauver3, Yue Gao5, Yao Jiang5, Darlene M Rozewski5, Ming Poi5, Mitch A Phelps6, Erica Harper3, Amy J Johnson4, John C Byrd4, Leslie A Andritsos4.   

Abstract

Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5mg followed by 5.0mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic Lymphocytic Leukemia; Lenalidomide; Maintenance; Relapse; Tumor flare

Mesh：

Substances：

Year:  2014        PMID： 25082342      PMCID： PMC4312491          DOI： 10.1016/j.leukres.2014.05.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  22 in total

1.  Dose escalation of lenalidomide in relapsed or refractory acute leukemias.

Authors:  William Blum; Rebecca B Klisovic; Heiko Becker; Xiaoxia Yang; Darlene M Rozewski; Mitch A Phelps; Ramiro Garzon; Alison Walker; Jason C Chandler; Susan P Whitman; John Curfman; Shujun Liu; Larry Schaaf; Jon Mickle; Cheryl Kefauver; Steven M Devine; Michael R Grever; Guido Marcucci; John C Byrd
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

2.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Authors:  Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert L Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

3.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Authors:  Asher Chanan-Khan; Kena C Miller; Laurie Musial; David Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David Spaner; Alice Mohr; Catriona Byrne; Francisco Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

4.  Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

Authors:  Nishitha Reddy; Francisco J Hernandez-Ilizaliturri; George Deeb; Mark Roth; Mary Vaughn; Joy Knight; Paul Wallace; Myron S Czuczman
Journal:  Br J Haematol       Date:  2007-11-09       Impact factor: 6.998

5.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

6.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

7.  Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.

Authors:  Georg Aue; Ndegwa Njuguna; Xin Tian; Susan Soto; Thomas Hughes; Berengere Vire; Keyvan Keyvanfar; Federica Gibellini; Janet Valdez; Carol Boss; Leigh Samsel; J Philip McCoy; Wyndham H Wilson; Stefania Pittaluga; Adrian Wiestner
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

8.  Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Authors:  Thomas E Witzig; Peter H Wiernik; Timothy Moore; Craig Reeder; Craig Cole; Glen Justice; Henry Kaplan; Michael Voralia; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Julie M Vose
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

9.  Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Thomas M Habermann; Izidore S Lossos; Glen Justice; Julie M Vose; Peter H Wiernik; Kyle McBride; Kenton Wride; Annette Ervin-Haynes; Kenichi Takeshita; Dennis Pietronigro; Jerome B Zeldis; Joseph M Tuscano
Journal:  Br J Haematol       Date:  2009-02-24       Impact factor: 6.998

10.  Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.

Authors:  David P Mangiameli; Joseph A Blansfield; Stephan Kachala; Dominique Lorang; Peter H Schafer; George W Muller; David I Stirling; Steven K Libutti
Journal:  J Transl Med       Date:  2007-07-18       Impact factor: 5.531
View more
  4 in total

1.  Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Authors:  Jim H Hughes; Mitch A Phelps; Richard N Upton; Stephanie E Reuter; Yue Gao; John C Byrd; Michael R Grever; Craig C Hofmeister; Guido Marcucci; William Blum; Kristie A Blum; David J R Foster
Journal:  Br J Clin Pharmacol       Date:  2019-02-27       Impact factor: 4.335

2.  Low-dose chemotherapeutic drugs induce reactive oxygen species and initiate apoptosis-mediated genomic instability.

Authors:  Renganathan Arun; Sridaran Dhivya; Suresh K Abraham; Kumpati Premkumar
Journal:  Toxicol Res (Camb)       Date:  2016-01-07       Impact factor: 3.524

3.  Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice.

Authors:  Jim H Hughes; Richard N Upton; Stephanie E Reuter; Darlene M Rozewski; Mitch A Phelps; David J R Foster
Journal:  Cancer Chemother Pharmacol       Date:  2019-09-06       Impact factor: 3.333

4.  Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Authors:  Maria Winqvist; Fariba Mozaffari; Marzia Palma; Sandra Eketorp Sylvan; Lotta Hansson; Håkan Mellstedt; Anders Österborg; Jeanette Lundin
Journal:  Cancer Immunol Immunother       Date:  2016-11-04       Impact factor: 6.968
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.